Posted by Michael Wonder on 15 Feb 2022
Pembrolizumab in combination with chemotherapy: significant additional benefit in advanced squamous cell carcinoma of the oesophagus
15 February 2022 - Those affected survived a median of 14 months compared to nine in the control group. However, an added benefit is not proven for patients with advanced adenocarcinoma.
Pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy is approved for the first-line treatment of adults with locally advanced, unresectable, or metastatic oesophageal squamous cell carcinoma or adenocarcinoma with PD-L1 expressing tumours.
